Covance Launches Managed Markets Services
Covance Inc., one of the world's largest and most comprehensive drug development services companies, announced the creation of a new service offering focused on providing its biopharmaceutical and medical device clients support to effectively manage contracts in managed markets. Steve Medina, Vice President, Managed Market Services, is leading this new effort.
Covance's managed markets services will help clients maximise value by improving controls and management of contract terms and associated payments. The new service will also help biopharmaceutical and medical device clients obtain higher market share by gaining better visibility into contract performance with managed care organisations, group purchasing organisations, federal and state programmes, and wholesalers.
The service targets a substantial need in the marketplace as chargebacks and rebates used in contracts account for as much as 20% of US gross sales for biopharmaceutical and medical device companies (approximately $50 billion a year). Without the right controls and contracting processes in place, biopharmaceutical and medical device companies risk both revenue loss and potential penalties associated with a failure to comply with government regulations. It is estimated that biopharmaceutical and medical device companies currently lose up to 4.4% of US revenue per year, or $11 billion a year, due to insufficient processes and contract management systems at a time when the economic environment for the sale of drugs and devices has never been more challenging.
"Covance is pleased to have invested in the expertise and technology to help biopharmaceutical and medical device clients prevent significant annual revenue losses from insufficient oversight of the contracts that are used to negotiate price and formulary placement with insurance companies, wholesalers and the government," said Marc Ginsky, Vice President and General Manager, Covance Market Access Services. "These contracts have become increasingly complex during the past several years and the acquisition and maintenance of the talent and technical infrastructure required to set up, maintain, and manage contracts without revenue leakage is a significant struggle for our clients."
"Covance's managed markets services can transform a labour-intensive, time-consuming, and costly process into a far simpler and more efficient service platform for our clients," said Steve Medina, Vice President, Managed Markets Services. "We believe that no other company currently offers a full-service, end-to-end solution across all types of contracts and services, with a full technical environment provided as part of the underlying service."
Covance's managed markets services will be led by Steve Medina, who joined Covance in July 2012. Medina came to Covance from HighPoint Solutions, where he was Vice President, Managed Service. Prior to this, Medina was the Practice Leader of the BTS Delivery Services Organization within IMS Health, the delivery services organization responsible for providing specialized solutions and on-going services to life sciences companies. His career includes 23 years of consulting, focused on health care product manufacturing. He specializes in ongoing service solutions, account management, and systems implementation. Medina has extensive experience with contract management, as well as sales and marketing.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...